Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232349 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Galantamine to Treat Schizophrenia
A Phase 4 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Terminated
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT00232349: Clinical Trial Phase 4 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT00232349 is a Phase 4 study that was terminated before completion, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 21 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232349, a Phase 4 study, was terminated before completion, sponsored by Seattle Institute for Biomedical and Clinical Research.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if treatment with adjunctive galantamine is effective in the reduction of functional impairments in patients with schizophrenia and schizoaffective disorder. It was hypothesized that adjunctive galantamine would yield clinically significant improvements from baseline to end of study on a measure of quality of life and a measure of independent living skills.
Interventions
- DRUG galantamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
Why NCT00232349 stopped before completion
NCT00232349 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which galantamine is the first listed.
NCT00232349 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00232349 about?
NCT00232349 is a clinical study titled "Efficacy of Galantamine to Treat Schizophrenia". The purpose of this study was to determine if treatment with adjunctive galantamine is effective in the reduction of functional impairments in patients with schizophrenia and schizoaffective disorder. It was hypothesized that adjunctive galantamine would yield clinically significant improvements fro...
What is the current status of trial NCT00232349?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2005-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00232349?
The interventions under investigation include: galantamine (DRUG).
Who is sponsoring clinical trial NCT00232349?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00232349's enrollment target sits among peer trials
21 1742nd of 2000 higher than 248 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia